You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDexmedetomidine
Accession NumberDB00633  (APRD00578)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionAn agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine. [PubChem]
Structure
Thumb
Synonyms
(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole
(+)-medetomidine
(S)-medetomidine
Dexmedetomidin
Dexmedetomidina
Dexmédétomidine
Dexmedetomidinum
External Identifiers
  • MPV 1440
  • MPV 785
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dexmedetomidine Hydrochlorideinjection, solution, concentrate100 ug/mLintravenousWG Critical Care, LLC2016-04-19Not applicableUs
Dexmedetomidine Hydrochlorideinjection, solution, concentrate100 ug/mLintravenousWG Critical Care, LLC2016-04-19Not applicableUs
Dexmedetomidine Hydrochlorideinjection, solution, concentrate100 ug/mLintravenousSandoz Inc.2014-10-03Not applicableUs
Precedexinjection, solution, concentrate100 ug/mLintravenousHospira, Inc.1999-12-17Not applicableUs
Precedexinjection, solution4 ug/mLintravenousHospira, Inc.2013-03-13Not applicableUs
Precedexsolution4 mcgintravenousHospira Healthcare Corporation2016-05-09Not applicableCanada
Precedexsolution100 mcgintravenousHospira Healthcare Corporation2010-02-24Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dexmedetomidineinjection, solution, concentrate100 ug/mLintravenousAkorn, Inc.2014-11-24Not applicableUs
Dexmedetomidine Hydrochlorideinjection, solution100 ug/mLintravenousAuro Medics Pharma Llc2016-03-17Not applicableUs
Dexmedetomidine Hydrochlorideinjection, solution, concentrate100 ug/mLintravenousMylan Institutional LLC2014-08-18Not applicableUs
Dexmedetomidine Hydrochlorideinjection, solution, concentrate100 ug/mLintravenousPar Pharmaceutical, Inc.2014-08-19Not applicableUs
Dexmedetomidine Hydrochlorideinjection, solution, concentrate100 ug/mLintravenousMylan Institutional LLC2015-06-09Not applicableUs
Dexmedetomidine Hydrochlorideinjection, solution100 ug/mLintravenousSun Pharmaceuticals Industries Inc.2015-04-08Not applicableUs
Dexmedetomidine Hydrochlorideinjection, solution, concentrate100 ug/mLintravenousMylan Institutional LLC2015-06-02Not applicableUs
Dexmedetomidine Hydrochlorideinjection, solution100 ug/mLintravenousFresenius Kabi USA, LLC2015-09-18Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DexdorOrion
DexemThemis Medicare
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Dexmedetomidine hydrochloride
ThumbNot applicableDBSALT001013
Categories
UNII67VB76HONO
CAS number113775-47-6
WeightAverage: 200.2795
Monoisotopic: 200.131348522
Chemical FormulaC13H16N2
InChI KeyInChIKey=CUHVIMMYOGQXCV-NSHDSACASA-N
InChI
InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)/t11-/m0/s1
IUPAC Name
4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
SMILES
C[[email protected]](C1=CNC=N1)C1=C(C)C(C)=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassNot Available
Direct ParentBenzene and substituted derivatives
Alternative Parents
Substituents
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting, also used in pain relief; anxiety reduction and analgesia
PharmacodynamicsDexmedetomidine activates 2-adrenoceptors, and causes the decrease of sympathetic tone, with attenuation of the neuroendocrine and hemodynamic responses to anesthesia and surgery; it reduces anesthetic and opioid requirements; and causes sedation and analgesia.
Mechanism of actionDexmedetomidine is a specific and selective alpha-2 adrenoceptor agonist. By binding to the presynaptic alpha-2 adrenoceptors, it inhibits the release if norepinephrine, therefore, terminate the propagation of pain signals. Activation of the postsynaptic alpha-2 adrenoceptors inhibits the sympathetic activity decreases blood pressure and heart rate.
Related Articles
AbsorptionNot Available
Volume of distribution
  • 118 L
Protein binding94%
Metabolism

Hepatic

Route of eliminationA mass balance study demonstrated that after nine days an average of 95% of the radioactivity, following intravenous administration of radiolabeled dexmedetomidine, was recovered in the urine and 4% in the feces. Fractionation of the radioactivity excreted in urine demonstrated that products of N-glucuronidation accounted for approximately 34% of the cumulative urinary excretion. The majority of metabolites are excreted in the urine.
Half life2 hours
Clearance
  • 39 L/h [Healthy volunteers receiving IV infusion (0.2-0.7 mcg/kg/hr)]
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9928
Blood Brain Barrier+0.9663
Caco-2 permeable+0.5471
P-glycoprotein substrateNon-substrate0.7118
P-glycoprotein inhibitor INon-inhibitor0.8925
P-glycoprotein inhibitor IINon-inhibitor0.9845
Renal organic cation transporterNon-inhibitor0.824
CYP450 2C9 substrateNon-substrate0.8067
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7558
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.5083
CYP450 2D6 inhibitorNon-inhibitor0.8218
CYP450 2C19 inhibitorInhibitor0.8564
CYP450 3A4 inhibitorInhibitor0.5684
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6714
Ames testNon AMES toxic0.6167
CarcinogenicityNon-carcinogens0.9178
BiodegradationNot ready biodegradable0.948
Rat acute toxicity2.4712 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9581
hERG inhibition (predictor II)Non-inhibitor0.9236
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Hospira inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionintravenous100 ug/mL
Injection, solutionintravenous4 ug/mL
Injection, solution, concentrateintravenous100 ug/mL
Solutionintravenous100 mcg
Solutionintravenous4 mcg
Prices
Unit descriptionCostUnit
Precedex 200 mcg/2 ml vial41.32USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1337659 No1995-11-282012-11-28Canada
CA2326339 No2008-12-232019-03-31Canada
US5344840 No1994-09-062011-09-06Us
US6716867 Yes1999-10-012019-10-01Us
US8242158 Yes2012-07-042032-07-04Us
US8338470 Yes2012-07-042032-07-04Us
US8455527 Yes2012-07-042032-07-04Us
US8648106 Yes2012-07-042032-07-04Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityFreely soluble in waterNot Available
logP2.8Not Available
pKa7.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.174 mg/mLALOGPS
logP3.28ALOGPS
logP3.39ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)6.54ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area28.68 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity62.98 m3·mol-1ChemAxon
Polarizability23.32 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Inese Reine, Armands Zandersons, “METHOD FOR PREPARING MEDETOMIDINE AND ITS SALTS..” U.S. Patent US20100048915, issued February 25, 2010.

US20100048915
General ReferencesNot Available
External Links
ATC CodesN05CM18
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (43.9 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with 7-Nitroindazole.
AcebutololThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Aceprometazine.
AcetazolamideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Acetazolamide.
adipiplonThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Agomelatine.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Dexmedetomidine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Alfentanil.
AliskirenThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Aliskiren.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dexmedetomidine.
AlprenololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Alprenolol.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Dexmedetomidine.
AmineptineThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Amineptine.
AmiodaroneDexmedetomidine may increase the bradycardic activities of Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Amisulpride.
AmitriptylineThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Amitriptyline.
AmitriptylineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Amitriptyline.
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Dexmedetomidine.
AmobarbitalAmobarbital may increase the hypotensive activities of Dexmedetomidine.
AmobarbitalThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Amperozide.
Amyl NitriteThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Amyl Nitrite.
ApraclonidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Apraclonidine.
AripiprazoleAripiprazole may increase the hypotensive activities of Dexmedetomidine.
AripiprazoleThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Aripiprazole.
ArotinololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.
ArticaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Asenapine.
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Dexmedetomidine.
AzaperoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Azaperone.
AzelastineDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Dexmedetomidine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Azilsartan medoxomil.
BaclofenThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Baclofen.
BarbitalBarbital may increase the hypotensive activities of Dexmedetomidine.
BarbitalThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Barbital.
BefunololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Dexmedetomidine.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Dexmedetomidine.
BenzocaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Benzyl alcohol.
BeractantDexmedetomidine may increase the bradycardic activities of Beractant.
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Dexmedetomidine.
BevantololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Dexmedetomidine.
BopindololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
BretyliumBretylium may increase the bradycardic activities of Dexmedetomidine.
BretyliumThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Bretylium.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.
BrimonidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Brotizolam.
BufuralolDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bufuralol.
BumetanideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dexmedetomidine.
BupranololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dexmedetomidine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dexmedetomidine.
ButacaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dexmedetomidine.
CalfactantDexmedetomidine may increase the bradycardic activities of Calfactant.
CanagliflozinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Canagliflozin.
CandesartanThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Candesartan.
CaptoprilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dexmedetomidine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Carisoprodol.
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Dexmedetomidine.
CarvedilolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Carvedilol.
CeliprololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Celiprolol.
CeritinibDexmedetomidine may increase the bradycardic activities of Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dexmedetomidine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chloroprocaine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dexmedetomidine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Dexmedetomidine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chlorzoxazone.
CilazaprilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Cilazapril.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dexmedetomidine.
CitalopramThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Clemastine.
ClevidipineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Clevidipine.
ClidiniumThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Clomipramine.
ClomipramineThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Dexmedetomidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dexmedetomidine.
ClotrimazoleThe metabolism of Dexmedetomidine can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dexmedetomidine.
CocaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dexmedetomidine.
CrizotinibDexmedetomidine may increase the bradycardic activities of Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Cyclizine.
CyclobenzaprineThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Cyclobenzaprine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Cyclobenzaprine.
CyproheptadineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Dexmedetomidine can be decreased when it is combined with Cyproterone acetate.
DantroleneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dantrolene.
DapagliflozinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dexmedetomidine.
DapoxetineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Desflurane.
DesipramineThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Desloratadine.
DesvenlafaxineDesvenlafaxine may decrease the antihypertensive activities of Dexmedetomidine.
DetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dexbrompheniramine.
DextromoramideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Diazepam.
DiclofenamideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Diclofenamide.
DifenoxinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Difenoxin.
DigoxinDigoxin may increase the bradycardic activities of Dexmedetomidine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dihydromorphine.
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Dexmedetomidine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dimenhydrinate.
DinutuximabThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dinutuximab.
DiphenhydramineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Diphenoxylate.
DipyridamoleThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dipyridamole.
DisulfiramThe metabolism of Dexmedetomidine can be decreased when combined with Disulfiram.
DonepezilDexmedetomidine may increase the bradycardic activities of Donepezil.
DoramectinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Doramectin.
DosulepinThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Dosulepin.
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Dexmedetomidine.
DoxepinThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Doxepin.
DoxepinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.
DoxylamineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.
DronedaroneDexmedetomidine may increase the bradycardic activities of Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Dexmedetomidine.
DrotebanolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Drotebanol.
DuloxetineDexmedetomidine may increase the orthostatic hypotensive activities of Duloxetine.
DuloxetineDuloxetine may decrease the antihypertensive activities of Dexmedetomidine.
DyclonineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Efavirenz.
EmpagliflozinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Empagliflozin.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Dexmedetomidine.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Dexmedetomidine.
EntacaponeThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Entacapone.
EplerenoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Eplerenone.
EprosartanThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Eprosartan.
EscitalopramThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Escitalopram.
EsmirtazapineThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Esmirtazapine.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Dexmedetomidine.
EstazolamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dexmedetomidine.
Etacrynic acidThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Etacrynic acid.
EthanolDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Dexmedetomidine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dexmedetomidine.
EthosuximideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dexmedetomidine.
EtoperidoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Etorphine.
EzogabineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Felbamate.
FelodipineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dexmedetomidine.
FexofenadineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fexofenadine.
FingolimodDexmedetomidine may increase the bradycardic activities of Fingolimod.
FlibanserinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dexmedetomidine.
FlurazepamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fluvoxamine.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Dexmedetomidine.
FosphenytoinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fospropofol.
FurosemideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Furosemide.
GabapentinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with gabapentin enacarbil.
GalantamineDexmedetomidine may increase the bradycardic activities of Galantamine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Glutethimide.
GuanfacineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Halazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dexmedetomidine.
HalothaneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Heroin.
HexobarbitalHexobarbital may increase the hypotensive activities of Dexmedetomidine.
HexobarbitalThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Hexobarbital.
HydralazineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Hydralazine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Hydrocodone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dexmedetomidine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.
HydroxyzineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Iloperidone.
ImipramineThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Indapamide.
IndenololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Indenolol.
IrbesartanThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Irbesartan.
IsofluraneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Isoflurane.
IsoniazidThe metabolism of Dexmedetomidine can be decreased when combined with Isoniazid.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Isosorbide Mononitrate.
IsoxsuprineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Isoxsuprine.
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Dexmedetomidine.
IvabradineDexmedetomidine may increase the bradycardic activities of Ivabradine.
KetamineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ketobemidone.
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Dexmedetomidine.
LacosamideDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LamotrigineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lamotrigine.
LanreotideDexmedetomidine may increase the bradycardic activities of Lanreotide.
LevetiracetamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Levetiracetam.
LevobunololThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Levocetirizine.
LevodopaDexmedetomidine may increase the orthostatic hypotensive activities of Levodopa.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Dexmedetomidine.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Levomilnacipran.
LevomilnacipranLevomilnacipran may decrease the antihypertensive activities of Dexmedetomidine.
LevorphanolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dexmedetomidine.
LisinoprilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dexmedetomidine.
LosartanThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Losartan.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dexmedetomidine.
Lu AA21004The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lu AA21004.
LucinactantDexmedetomidine may increase the bradycardic activities of Lucinactant.
LurasidoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Maprotiline.
MecamylamineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Mecamylamine.
MeclizineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dexmedetomidine.
MesoridazineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Dexmedetomidine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methaqualone.
MethazolamideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methocarbamol.
MethohexitalMethohexital may increase the hypotensive activities of Dexmedetomidine.
MethohexitalThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methohexital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dexmedetomidine.
MethyldopaThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methyldopa.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Dexmedetomidine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methylphenobarbital.
MetipranololThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Metipranolol.
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Dexmedetomidine.
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Dexmedetomidine.
MetyrosineDexmedetomidine may increase the sedative activities of Metyrosine.
MianserinThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Mianserin.
MidazolamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Midazolam.
MilnacipranThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Milnacipran.
MilnacipranMilnacipran may decrease the antihypertensive activities of Dexmedetomidine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Dexmedetomidine.
MirtazapineDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Mirtazapine.
MoexiprilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dexmedetomidine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.
NabiloneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nabilone.
NadololThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nadolol.
NalbuphineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nalbuphine.
NebivololThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nebivolol.
NesiritideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nesiritide.
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Dexmedetomidine.
NicorandilNicorandil may increase the hypotensive activities of Dexmedetomidine.
NicotineThe metabolism of Dexmedetomidine can be decreased when combined with Nicotine.
NifedipineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nifedipine.
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Dexmedetomidine.
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Dexmedetomidine.
NitrazepamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nitrazepam.
NitroglycerinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nitroglycerin.
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Dexmedetomidine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Normethadone.
NortriptylineThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Nortriptyline.
NortriptylineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nortriptyline.
OctreotideOctreotide may increase the bradycardic activities of Dexmedetomidine.
OlanzapineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Olanzapine.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Dexmedetomidine.
OlopatadineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Opium.
OrphenadrineDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dexmedetomidine.
OsanetantThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dexmedetomidine.
OxymorphoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Oxymorphone.
PaliperidoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Paliperidone.
PapaverineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Papaverine.
ParaldehydeDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Dexmedetomidine.
ParoxetineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Paroxetine.
PasireotideDexmedetomidine may increase the bradycardic activities of Pasireotide.
PenbutololThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pentazocine.
PentobarbitalPentobarbital may increase the hypotensive activities of Dexmedetomidine.
PentobarbitalThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pentobarbital.
PerampanelThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Perampanel.
PerindoprilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dexmedetomidine.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Dexmedetomidine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pimozide.
PindololThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pindolol.
PipamperoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pomalidomide.
Poractant alfaDexmedetomidine may increase the bradycardic activities of Poractant alfa.
PractololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Practolol.
PramipexoleDexmedetomidine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Prazepam.
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Dexmedetomidine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dexmedetomidine.
PrilocaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Prilocaine.
PrimidonePrimidone may increase the hypotensive activities of Dexmedetomidine.
PrimidoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Procaine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dexmedetomidine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Dexmedetomidine.
PromethazineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Promethazine.
PropafenoneDexmedetomidine may increase the bradycardic activities of Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Propoxycaine.
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Dexmedetomidine.
ProtriptylineThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Protriptyline.
ProtriptylineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Quetiapine.
QuinaprilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Quinapril.
RamelteonThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ramelteon.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Dexmedetomidine.
RemifentanilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dexmedetomidine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dexmedetomidine.
RiociguatThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Riociguat.
RisperidoneDexmedetomidine may increase the hypotensive activities of Risperidone.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Dexmedetomidine.
RivastigmineDexmedetomidine may increase the bradycardic activities of Rivastigmine.
RomifidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Romifidine.
RopiniroleDexmedetomidine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dexmedetomidine.
RotigotineDexmedetomidine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dexmedetomidine.
RuxolitinibRuxolitinib may increase the bradycardic activities of Dexmedetomidine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Scopolamine.
SecobarbitalSecobarbital may increase the hypotensive activities of Dexmedetomidine.
SecobarbitalThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Secobarbital.
SertindoleThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Sevoflurane.
Sodium oxybateThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Sodium oxybate.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Dexmedetomidine.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Dexmedetomidine.
StiripentolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Stiripentol.
SufentanilDexmedetomidine may increase the bradycardic activities of Sufentanil.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dexmedetomidine.
SuvorexantThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tasimelteon.
TelmisartanThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dexmedetomidine.
TerazosinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Terazosin.
TetrabenazineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tetrodotoxin.
ThalidomideDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dexmedetomidine.
ThiamylalThiamylal may increase the hypotensive activities of Dexmedetomidine.
ThiamylalThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Thiamylal.
ThiopentalThiopental may increase the hypotensive activities of Dexmedetomidine.
ThiopentalThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Thiopental.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Dexmedetomidine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dexmedetomidine.
ThiothixeneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tiagabine.
TianeptineThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Tianeptine.
TiclopidineThe metabolism of Dexmedetomidine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tiletamine.
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Dexmedetomidine.
TizanidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tizanidine.
TofacitinibTofacitinib may increase the bradycardic activities of Dexmedetomidine.
TolcaponeThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Topiramate.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Dexmedetomidine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dexmedetomidine.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Dexmedetomidine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Trazodone.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Dexmedetomidine.
TriazolamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dexmedetomidine.
TrimipramineThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Trimipramine.
TrimipramineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Dexmedetomidine.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Dexmedetomidine.
VenlafaxineVenlafaxine may decrease the antihypertensive activities of Dexmedetomidine.
VerapamilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dexmedetomidine.
ZolazepamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Dexmedetomidine.
ZonisamideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Fairbanks CA, Stone LS, Kitto KF, Nguyen HO, Posthumus IJ, Wilcox GL: alpha(2C)-Adrenergic receptors mediate spinal analgesia and adrenergic-opioid synergy. J Pharmacol Exp Ther. 2002 Jan;300(1):282-90. [PubMed:11752127 ]
  2. Scheibner J, Trendelenburg AU, Hein L, Starke K, Blandizzi C: Alpha 2-adrenoceptors in the enteric nervous system: a study in alpha 2A-adrenoceptor-deficient mice. Br J Pharmacol. 2002 Feb;135(3):697-704. [PubMed:11834617 ]
  3. Davies MF, Tsui J, Flannery JA, Li X, DeLorey TM, Hoffman BB: Activation of alpha2 adrenergic receptors suppresses fear conditioning: expression of c-Fos and phosphorylated CREB in mouse amygdala. Neuropsychopharmacology. 2004 Feb;29(2):229-39. [PubMed:14583739 ]
  4. Dawson C, Ma D, Chow A, Maze M: Dexmedetomidine enhances analgesic action of nitrous oxide: mechanisms of action. Anesthesiology. 2004 Apr;100(4):894-904. [PubMed:15087625 ]
  5. Ozdogan UK, Lahdesmaki J, Hakala K, Scheinin M: The involvement of alpha 2A-adrenoceptors in morphine analgesia, tolerance and withdrawal in mice. Eur J Pharmacol. 2004 Aug 23;497(2):161-71. [PubMed:15306201 ]
  6. Menon DV, Wang Z, Fadel PJ, Arbique D, Leonard D, Li JL, Victor RG, Vongpatanasin W: Central sympatholysis as a novel countermeasure for cocaine-induced sympathetic activation and vasoconstriction in humans. J Am Coll Cardiol. 2007 Aug 14;50(7):626-33. Epub 2007 Jul 30. [PubMed:17692748 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Avsaroglu H, Bull S, Maas-Bakker RF, Scherpenisse P, Van Lith HA, Bergwerff AA, Hellebrekers LJ, Van Zutphen LF, Fink-Gremmels J: Differences in hepatic cytochrome P450 activity correlate with the strain-specific biotransformation of medetomidine in AX/JU and IIIVO/JU inbred rabbits. J Vet Pharmacol Ther. 2008 Aug;31(4):368-77. doi: 10.1111/j.1365-2885.2008.00969.x. [PubMed:18638298 ]
  2. Duhamel MC, Troncy E, Beaudry F: Metabolic stability and determination of cytochrome P450 isoenzymes' contribution to the metabolism of medetomidine in dog liver microsomes. Biomed Chromatogr. 2010 Aug;24(8):868-77. doi: 10.1002/bmc.1379. [PubMed:20020418 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Konstandi M, Lang MA, Kostakis D, Johnson EO, Marselos M: Predominant role of peripheral catecholamines in the stress-induced modulation of CYP1A2 inducibility by benzo(alpha)pyrene. Basic Clin Pharmacol Toxicol. 2008 Jan;102(1):35-44. Epub 2007 Oct 31. [PubMed:17973897 ]
  2. Konstandi M, Kostakis D, Harkitis P, Johnson EO, Marselos M, Adamidis K, Lang MA: Benzo(alpha)pyrene-induced up-regulation of CYP1A2 gene expression: role of adrenoceptor-linked signaling pathways. Life Sci. 2006 Jun 20;79(4):331-41. Epub 2006 Feb 28. [PubMed:16510159 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Konstandi M, Kostakis D, Harkitis P, Marselos M, Johnson EO, Adamidis K, Lang MA: Role of adrenoceptor-linked signaling pathways in the regulation of CYP1A1 gene expression. Biochem Pharmacol. 2005 Jan 15;69(2):277-87. [PubMed:15627480 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Rodrigues AD, Roberts EM: The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6). Drug Metab Dispos. 1997 May;25(5):651-5. [PubMed:9152607 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 28, 2016 03:41